4.4 Article

Comparison of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Heart Valves

期刊

AMERICAN JOURNAL OF CARDIOLOGY
卷 146, 期 -, 页码 22-28

出版社

EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjcard.2021.01.016

关键词

-

资金

  1. Edwards Lifesciences Doctoral Fellowship

向作者/读者索取更多资源

This study evaluated the ambulatory utilization of DOACs and compared the effectiveness and safety of DOACs versus warfarin in patients with bioprosthetic heart valves and atrial fibrillation. The findings suggest that DOACs have a lower risk of safety outcomes compared with warfarin, though there was no significant difference in effectiveness outcomes between the two groups.
There are limited data regarding direct oral anticoagulants (DOACs) for stroke prevention in patients with bioprosthetic heart valves (BHVs) and atrial fibrillation (AF). The objectives of this study were to evaluate the ambulatory utilization of DOACs and to compare the effectiveness and safety of DOACs versus warfarin in patients with AF and BHVs. We conducted a retrospective cohort study at a large integrated health care delivery system in California. Patients with BHVs and AF treated with warfarin, dabigatran, rivaroxaban, or apixaban between September 12, 2011 and June 18, 2020 were identified. Inverse probability of treatment-weighted comparative effectiveness and safety of DOACs compared with warfarin were determined. Use of DOACs gradually increased since 2011, with a significant upward in trend after a stay-at-home order related to COVID-19. Among 2,672 adults with BHVs and AF who met the inclusion criteria, 439 were exposed to a DOAC and 2233 were exposed to warfarin. For the primary effectiveness outcome of ischemic stroke, systemic embolism and transient ischemic attack, no significant association was observed between use of DOACs compared with warfarin (HR 1.19, 95% CI 0.96 to 1.48, p = 0.11). Use of DOACs was associated with lower risk of the primary safety outcome of intracranial hemorrhage, gastrointestinal bleeding, and other bleed (HR 0.69, 95% CI 0.56 to 0.85, p < 0.001). Results were consistent across multiple subgroups in the sensitivity analyses. These findings support the use of DOACs for AF in patients with BHVs. ? 2021 Elsevier Inc. All rights reserved. (Am J Cardiol 2021;146:22?28)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据